CVRx
Yahoo Finance • 8 days ago
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, to... Full story
Yahoo Finance • 29 days ago
CVRx sees Q1 revenue in the range of $14.7M to $14.8M
* CVRx (CVRX [https://seekingalpha.com/symbol/CVRX]) on Monday said total revenue for the first quarter of 2026 is expected to be in the range of $14.7 million to $14.8 million compared to revenue for the first quarter of 2025 of $12.3 m... Full story
Yahoo Finance • 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.co... Full story
Yahoo Finance • 3 months ago
CVRx outlines $63M-$67M 2026 revenue target as Barostim adoption accelerates with new CPT code
Earnings Call Insights: CVRx (CVRX) Q4 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, highlighted fourth quarter revenue of $16 million and full year revenue of $56.7 million, noting "growth of 4% and 10%, respectively." Hykes... Full story
Yahoo Finance • 6 months ago
CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference
MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 6 months ago
CVRx anticipates mid-teens growth in 2026 as sales force productivity and reimbursement improvements build momentum
Earnings Call Insights: CVRx, Inc. (CVRX) Q3 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, stated that "Q3 was a strong quarter for CVRx. We grew revenue by double digits year-over-year and expanded our commercial footprint."... Full story
Yahoo Finance • 7 months ago
CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025
MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 9 months ago
CVRx outlines $55M-$57M revenue target for 2025 as sales force transition nears completion
Earnings Call Insights: CVRx (CVRX) Q2 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, announced "total revenue of $13.6 million in the second quarter, a 15% increase over the same quarter last year." U.S. Heart Failure revenue... Full story
Yahoo Finance • 9 months ago
CVRx GAAP EPS of -$0.57 misses by $0.05, revenue of $13.6M beats by $0.38M
* CVRx press release [https://seekingalpha.com/pr/20188110-cvrx-reports-second-quarter-2025-financial-and-operating-results] (NASDAQ:CVRX [https://seekingalpha.com/symbol/CVRX]): Q2 GAAP EPS of -$0.57 misses by $0.05. * Revenue of $13.... Full story
Yahoo Finance • 9 months ago
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 10 months ago
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 10 months ago
CVRx shares rise on CMS inclusion for Barostim implant procedure
[doctor working in hospital laboratory] sinology/Moment via Getty Images * CVRx (NASDAQ:CVRX [https://seekingalpha.com/symbol/CVRX]) saw a 17% increase in its shares following the announcement that Centers for Medicare and Medicaid Serv... Full story
Yahoo Finance • 10 months ago
Medicare proposes to maintain payment for CVRx's Barostim procedure
MINNEAPOLIS - The Centers for Medicare and Medicaid Services (CMS) has proposed to keep CVRx’s Barostim implant procedure in the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,0... Full story
Yahoo Finance • 10 months ago
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim imp... Full story
Yahoo Finance • 11 months ago
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with c... Full story
Yahoo Finance • last year
CVRx Reports Preliminary First Quarter 2025 Financial Results
MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. “While we continue to make... Full story
Yahoo Finance • last year
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (T... Full story
Yahoo Finance • last year
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neur... Full story
Yahoo Finance • 2 years ago
CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference
MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with... Full story
Yahoo Finance • 3 years ago
CMS Increases Outpatient Payment for Barostim Procedure
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant proce... Full story